Etizolam +  Escitalopram

Etizolam + Escitalopram

Form: Tablets

Strength: Etizolam(0.25 mg-0.5 mg) + Escitalopram( 5 -10 mg)

Reference Brands: Etizola Plus, Nexito Plus, Stalopam Plus(India & in Asia)

Category: Antipsychotropic Drugs

Etizolam + Escitalopram is a fixed-dose combination used in the treatment of anxiety disorders with comorbid depression. Etizolam, a fast-acting anxiolytic, complements Escitalopram, a selective serotonin reuptake inhibitor (SSRI), to provide comprehensive relief from mood and anxiety symptoms. Though not approved in the US or EU due to regulatory classifications, this combination is widely prescribed in India and other Asian markets. It is typically available in tablet form in strengths like Etizolam 0.25/0.5 mg with Escitalopram 5/10 mg. B2B pharmaceutical suppliers often cater this formulation to psychiatrists, hospitals, and wellness clinics targeting neuropsychiatric care markets

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details Get Enquiry
Zuclopenthixol ong-acting IM Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details Get Enquiry
Zuclopenthixol Short-acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details Get Enquiry
Zuclopenthixol tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.